Researchers from the North Carolina State University, The Hamner Institutes for Health Sciences, and the National Institute of Environmental Health Sciences used a mouse model to examine the effect of inhalation of multi-walled carbon nanotubes on the lungs.

CanBas Co., Ltd. (Numazu, Shizuoka, “CanBas”) and Takeda Pharmaceutical Company Limited (Osaka, “Takeda”) together with Takeda’s wholly-owned subsidiary Millennium: The Takeda Oncology Company (Cambridge, MA, “Millennium”) today announced the advancement of CBP501 into Phase II clinical trials for the treatment of patients with non-small cell lung cancer (NSCLC). Current pre-clinical data suggest that CBP501 has the potential to induce cancer cell death through a mechanism of action that blocks the ability of cancer cells to transition through the cell cycle.

University medical experts are randomly selecting 1,200 taconite workers and 800 of their spouses for one of three health studies now under way to find out why so many Iron Rangers are dying from mesothelioma.